Affiliation:
1. Division of Infectious Diseases, UCLA School of Medicine 90024-1688, USA.
Abstract
Human protozoal infections are ubiquitous and occur worldwide. In many cases, antiprotozoal agents currently in use predate the modern antibiotic era. Despite the relative lag in development of new antiprotozoal agents, the 1990s have witnessed an increasing level of interest in these infections, inspired by international travel and immigration, a growing awareness of antiprotozoal drug resistance, and the significance of acute and recrudescent protozoal infections in immunosuppressed hosts. This review summarizes for nonclinician readers the past, present, and future therapies for common human protozoal infections, as well as pharmacologic mechanisms of action and resistance and common toxicities associated with these agents.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology
Reference182 articles.
1. Retrospective long-term study of effects of berenil by follow-up of patients treated since 1965;Abaru D. E.;Trop. Med. Parasitol.,1984
2. Cutaneous leishmaniasis in Kuwait: clinical experience with itraconazole;Al-Fouzan A. S.;Pharmacol. Ther.,1991
3. Therapeutic use of mebendazole in giardial infections;Al-Waili N. S.;Trans. R. Soc. Trop. Med. Hyg.,1988
4. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains;Andrade S. G.;Trans. R. Soc. Trop. Med. Hyg.,1992
5. Anonymous. 1989. Halofantrine in the treatment of malaria. Lancet ii:537-538.
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献